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Abstract: Panic disorder is the most common type of anxiety disorder, and its most common 
expression is panic attacks characterized with sudden attacks of anxiety with numerous symp-
toms, including palpitations, tachycardia, tachypnea, nausea, and vertigo: ie, cardiovascular, 
gastroenterologic, respiratory, and neuro-otologic symptoms. In clinical practice, panic disorder 
manifests with isolated gastroenteric or cardiovascular symptoms, requiring additional clinical 
visits after psychiatric intervention. The first-line treatment for anxiety disorders, and in particular 
for panic disorder, is the selective serotonin reuptake inhibitors. However, these drugs can have 
adverse effects, including sexual dysfunction, increased bodyweight, and abnormal bleeding, 
that may be problematic for some patients. Here we report the case of a 29-year-old Caucasian 
woman affected by panic disorder with agoraphobia who was referred to our clinic for recurrent 
gastroenteric panic symptoms. The patient reported improvement in her anxiety symptoms and 
panic attacks while on a selective serotonin reuptake inhibitor, but not in her gastric somatic 
problems, so the decision was taken to start her on duloxetine, a serotonin-norepinephrine 
reuptake inhibitor. After 6 months of treatment, the patient achieved complete remission of her 
gastric and panic-related symptoms, and was able to stop triple gastric therapy. Other authors 
have hypothesized and confirmed that duloxetine has greater initial noradrenergic effects than 
venlafaxine and is effective in patients with panic disorder. This case report underscores the pos-
sibility of tailoring therapeutic strategies for the gastroenteric expression of panic disorder.
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Introduction
Anxiety disorders are the most common type of psychiatric disorder, with a mean 
incidence of 18.1% and a lifetime prevalence of 28.8%.1 Panic attacks are the most 
common type of anxiety disorder, with lifetime prevalence estimates of 22.7% for 
isolated (ie, without panic disorder) panic attacks without agoraphobia, 0.8% for iso-
lated panic attacks with agoraphobia, 3.7% for panic disorder without agoraphobia, 
and 1.1% for panic disorder with agoraphobia. All four subgroups have significant 
comorbidity with other lifetime DSM-IV (Diagnostic and Statistical Manual of Men-
tal Disorders, 4th Edition) disorders, with the highest rates of comorbidity in panic 
disorder with agoraphobia and the lowest in isolated panic attacks.2 Panic attacks 
are characterized by sudden attacks of anxiety with numerous somatic symptoms, 
including palpitations, tachycardia, tachypnea, nausea, and vertigo (ie, cardiovascular, 
gastroenterologic, respiratory, and neuro-otologic symptoms). In clinical practice, 
panic disorder may also be observed with isolated gastroenteric or cardiovascular 
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symptoms requiring further clinical consultations following 
psychiatric intervention. Selective serotonin reuptake inhibi-
tors are the preferred treatment for anxiety disorders, and for 
panic disorder in particular. However, these drugs can have 
adverse effects, including sexual dysfunction,3 increased 
bodyweight,4 and abnormal bleeding,5 so their use may be 
problematic in some patients.
Case report
GV, a 29-year-old Caucasian woman suffering from panic 
disorder with agoraphobia, was referred to our clinic for 
recurrent gastroenteric panic symptoms. She had a negative 
family history for mental illness and had no past history 
of substance use/abuse. The patient’s psychiatric history 
dated back to 8 years previously when, at the age of 21 
years, she presented with somatic panic symptoms, ie, 
tachycardia, chest tightness, heartburn, and panic attacks. 
On her first outpatient visit to the gastroenterology clinic 
at the age of 26 years, she presented with recurrent heart-
burn, but tested negative for hiatal hernia, Helicobacter 
pylori, and esophagogastric reflux. At that time, she was 
also experiencing isolated panic attacks characterized by 
palpitations (tachycardia), chest tightness, somatopsychic 
depersonalization, fear of dying, anticipatory anxiety, harm 
avoidance, and a fear of being alone. She was not given 
any psychopharmacologic treatment but was treated with 
triple gastric therapy comprising a proton pump inhibitor 
(esomeprazole), antacids (alginic acid and sodium bicarbon-
ate), and an antidopaminergic gastrointestinal prokinetic 
agent (clebopride).
At the first outpatient visit, the patient presented pri-
marily with somatic symptoms, including heartburn, chest 
tightness and pain, somatopsychic depersonalization, 
tachycardia, and fear of dying and anxiety in the context of 
asthenia and  anergia. We assessed her symptomatology using 
the  Structured Clinical Interview for Panic-Agoraphobic 
Spectrum lifetime version,6 and the score was 85 at the 
first visit. We initially prescribed citalopram 20 mg/day, but 
the patient reported sexual dysfunction (reduction/loss of 
libido and difficulty achieving orgasm), cognitive impair-
ment, and fatigue. The patient reported improvement in her 
anxiety symptoms and panic attacks on a selective serotonin 
reuptake inhibitor, but not in her troublesome gastric somatic 
symptoms. We therefore decided to gradually reduce the dose 
of citalopram and introduced escitalopram 7 mg/day, but the 
patient continued to report loss of libido with no change in her 
gastric symptoms. We then prescribed duloxetine 30 mg/day, 
which was subsequently increased to 60 mg/day, with slow 
withdrawal of escitalopram. After 6 months of treatment, the 
patient showed complete remission of her gastric and panic-
related symptoms, and all three gastric treatments were able 
to be discontinued.
Discussion
This case report underscores the possibility of tailoring 
therapeutic strategies for the gastroenteric expression of 
panic disorder. Selective serotonin reuptake inhibitors remain 
the first-line treatment for panic disorder, and paroxetine 
is the gold standard among these psychopharmacologic 
medications.7,8 However, these drugs can have adverse 
effects, including sexual dysfunction, increased bodyweight, 
and abnormal bleeding, leading to problems with continua-
tion of therapy. The opportunity to have another therapeutic 
option with fewer adverse effects is important and helpful. 
Other researchers, such as Simon et al, have hypothesized 
and confirmed that duloxetine, a serotonin-norepinephrine 
reuptake inhibitor with greater initial noradrenergic effects 
than venlafaxine, has broad efficacy in individuals with panic 
disorder.9,10 Our interest in duloxetine lies in the possibility 
of treatment for panic disorder with the added benefit of 
resolution of gastric symptoms. As other researchers have 
pointed out, duloxetine acts on the neuropathic pain caused 
by fibromyalgia, neuropathic diabetes,11–13 and irritable bowel 
syndrome,14 and has fewer sexual and cognitive adverse 
effects. Moreover, descending serotonin and norepineph-
rine pathways have been suggested to be modulators of 
pain perception,15 and duloxetine has been shown to have 
an analgesic effect on painful physical symptoms that are 
partially independent of the improvement in major depres-
sive disorder.15,16
Our patient presented with panic disorder and a combi-
nation of gastroenteric symptoms in the context of asthe-
nia, anergia, and severe adverse effects due to treatment 
with a selective serotonin reuptake inhibitor, suggesting 
the possibility that a serotonin-norepinephrine reuptake 
inhibitor such as duloxetine may be of some value in 
patients presenting with such symptoms in a psychopatho-
logic context. Obviously, further research is warranted to 
replicate our clinical observations and, in general terms, 
controlled studies are needed to confirm the efficacy of 
this treatment.
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